Evidence map›Paper›PMID 41762250›Full record

ArticleCancer immunology, immunotherapy : CII2026

Integrative analysis of T cell subset-specific ICOS expression and tumor HLA class I/II expression in lung adenocarcinoma: implications for their interaction and clinical outcome.

Hiroyuki Yamada, Rin Yamada, Yoshihiro Komohara, Cheng Pan, Daiki Yoshii, Hiromu Yano, Eri Matsubara, Yusuke Shinchi, Hirotake Tsukamoto, Yukio Fujiwara and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hiroyuki YamadaDepartment of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.
Rin YamadaDepartment of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.
Yoshihiro KomoharaDepartment of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan. ycomo@kumamoto-u.ac.jp.
Cheng PanDepartment of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.
Daiki YoshiiDepartment of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.
Hiromu YanoDepartment of Tumor Pathology, Graduate School of Health Sciences, Kumamoto University, 4-24-1 Kuhonji, Chuo-Ku, Kumamoto, 862-0976, Japan.
Eri MatsubaraDepartment of Thoracic Surgery and Breast Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.
Yusuke ShinchiDepartment of Thoracic Surgery and Breast Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.
Hirotake TsukamotoDivision of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-Cho, Sakyo-Ku, Kyoto, 606-8501, Japan.
Yukio FujiwaraDepartment of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.
Koei IkedaDepartment of Thoracic Surgery and Breast Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.
Makoto SuzukiDepartment of Thoracic Surgery and Breast Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.

Funding

Ministry of Education, Culture, Sports, Science and Technology of Japan 20H03459
6 · The paper itself

Abstract

objectivesInducible T cell costimulator (ICOS) is a CD28-family costimulatory receptor with bidirectional therapeutic effects on antitumor immunity, and HLA-mediated tumor recognition is essential for effective T cell responses. However, their clinicopathological significance in lung adenocarcinoma (LUAD) is not fully understood. We investigated subset-specific pattern of ICOS expression and examined whether ICOS MATERIALS AND

methodsWe examined 228 resected LUADs by immunohistochemistry. ICOS

resultsICOS

conclusionIn LUAD, ICOS

Indexed as

Adenocarcinoma of LungHistocompatibility Antigens Class IHistocompatibility Antigens Class IIInducible T-Cell Co-Stimulator ProteinLung NeoplasmsLymphocytes, Tumor-InfiltratingT-Lymphocyte SubsetsAgedBiomarkers, TumorFemaleHumansMaleMiddle AgedPrognosisBiomarkers, TumorHistocompatibility Antigens Class IHistocompatibility Antigens Class IIICOS protein, humanInducible T-Cell Co-Stimulator ProteinCD278HLA class IHLA class IIInducible T cell costimulatorLung adenocarcinomaTumor-infiltrating lymphocyte

Identifiers

PMID41762250
PMCPMC12950126

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.